HemoGenyx Pharmaceuticals Plc (5HU0) Income Statement
HemoGenyx Pharmaceuticals Plc Income Statement
Last quarter (Q2 2026), HemoGenyx Pharmaceuticals Plc's total revenue was $0.00. In Q2, HemoGenyx Pharmaceuticals Plc's net income was $-6.55M. See HemoGenyx Pharmaceuticals Plc’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ -588.75K | $ -639.28K | $ -645.68K | $ -2.60M | $ -283.65K | |
| $ 4.07M | $ 5.09M | $ 4.91M | $ 2.93M | $ 2.70M | |
| Depreciation and Amortization | $ 588.75K | $ 639.28K | $ 645.68K | $ 564.07K | $ 126.34K |
| $ -4.07M | $ -4.71M | $ -5.73M | $ -3.42M | $ -2.39M | |
| $ -4.66M | $ -5.73M | $ -5.56M | $ 4.00M | $ -2.70M | |
| $ -5.11M | $ 101.22K | $ -1.14M | $ 1.54M | $ -2.41M | |
| $ -9.77M | $ -5.63M | $ -6.70M | $ -3.99M | $ -5.11M | |
| $ -9.76M | $ -5.62M | $ -6.69M | $ -3.98M | $ -5.10M | |
| Per Share Metrics | |||||
| Basic EPS | $ -2.20 | $ -1.70 | $ -2.37 | $ -1.62 | $ -2.64 |
| Diluted EPS | $ -2.20 | $ -1.70 | $ -2.37 | $ -1.62 | $ -2.64 |
| Weighted Average Shares Outstanding | 4.44M | 3.30M | 2.82M | 2.45M | 1.93M |
| Weighted Average Shares Outstanding (Diluted) | 4.44M | 3.30M | 2.82M | 2.45M | 1.93M |
Currency in GBP
